Bio News
Merck and Moderna reported positive results from a Phase 3 trial of the personalized mRNA cancer vaccine intismeran. The combination of intismeran and Keytruda improved recurrence-free survival and distant metastasis-free survival in 1,137 patients with completely resected, high-risk cutaneous melanoma. The companies plan to present the data at an international medical meeting and discuss a regulatory filing with health authorities.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
